Non-Aeruginosa Pseudomonas Species Isolated from Bacteremia Patients at a Tertiary Care Center in India: A Retrospective Study
Abstract
Human infection with non-aeruginosa Pseudomonas (NAP) is not commonly observed but can be severe and associated with significant morbidity and mortality. The aim for the present study was to investigate the prevalence, patient characteristics, risk factors, and clinical presentation of patients with NAP bacteremia. Additionally, the antibiotic sensitivity patterns of NAP isolates were assessed. The current retrospective study was conducted in the microbiology laboratory of a tertiary care center from January 2022 to October 2024. Two sets of blood cultures were received in BACTEC bottles (Becton, Dickinson and Company, Franklin Lakes, NJ) and were incubated. The blood samples were cultured on blood and MacConkey agar, and microscopy was performed using Gram staining. Species identification was performed via matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Antibiotic sensitivity testing was performed using meropenem, colistin, levofloxacin, amikacin, piperacillin-tazobactam, imipenem, aztreonam, ceftazidime, and cefoperazone-sulbactam. During the 2-year study period, 42 blood cultures grew Pseudomonas species other than Pseudomonas aeruginosa. The majority of patients were <60 years of age (76.1%). The age range of the population was 4-75 years. The male-to-female ratio of the population was 1.1:1. In this study, most isolates belonged to Pseudomonas mosselii (n = 13; 31%), followed by Pseudomonas stutzeri (n = 11; 26.1%), Pseudomonas putida (n =…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 34 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.